

# Katsutoshi Oda

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3577719/katsutoshi-oda-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

113  
papers

3,081  
citations

23  
h-index

53  
g-index

117  
ext. papers

3,527  
ext. citations

4.2  
avg, IF

4.46  
L-index

#	Paper	IF	Citations
113	The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma.. <i>Communications Biology</i> , <b>2022</b> , 5, 39	6.7	0
112	Genetic diagnosis of pseudomyxoma peritonei originating from mucinous borderline tumor inside an ovarian teratoma.. <i>BMC Medical Genomics</i> , <b>2022</b> , 15, 51	3.7	
111	Histone arginine methyltransferase CARM1 selective inhibitor TP-064 induces apoptosis in endometrial cancer.. <i>Biochemical and Biophysical Research Communications</i> , <b>2022</b> , 601, 123-128	3.4	0
110	Recurrent cervical cancer with PD-L1 amplification treated with nivolumab: A case enrolled in the BELIEVE trial.. <i>Journal of Obstetrics and Gynaecology Research</i> , <b>2022</b> ,		0
109	Tumor mutational burden measurement using comprehensive genomic profiling assay.. <i>Japanese Journal of Clinical Oncology</i> , <b>2022</b> ,	2.8	1
108	Effect of primary prophylaxis with pegfilgrastim in endometrial cancer patients treated with doxorubicin and cisplatin.. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , <b>2022</b> , 61, 265-269	1.6	1
107	Automated system for diagnosing endometrial cancer by adopting deep-learning technology in hysteroscopy. <i>PLoS ONE</i> , <b>2021</b> , 16, e0248526	3.7	10
106	A Placebo-Controlled, Double-Blind Randomized (Phase IIB) Trial of Oral Administration with HPV16 E7-Expressing , GLBL101c, for the Treatment of Cervical Intraepithelial Neoplasia Grade 2 (CIN2). <i>Vaccines</i> , <b>2021</b> , 9,	5.3	2
105	Enhanced antitumor activity of combined lipid bubble ultrasound and anticancer drugs in gynecological cervical cancers. <i>Cancer Science</i> , <b>2021</b> , 112, 2493-2503	6.9	5
104	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1). <i>International Journal of Clinical Oncology</i> , <b>2021</b> , 26, 233-283	4.2	20
103	Comprehensive immunohistochemical analysis of the gastrointestinal and Müllerian phenotypes of 139 ovarian mucinous cystadenomas. <i>Human Pathology</i> , <b>2021</b> , 109, 21-30	3.7	2
102	Cancer Genomic Profiling of Gynecological Malignancies by Todai OncoPanel, a Twin DNA and RNA Panel. <i>Current Human Cell Research and Applications</i> , <b>2021</b> , 27-39	0.1	
101	A low preoperative albumin-to-globulin ratio is a negative prognostic factor in patients with surgically treated cervical cancer. <i>International Journal of Clinical Oncology</i> , <b>2021</b> , 26, 980-985	4.2	1
100	Differential expression of human papillomavirus 16-, 18-, 52-, and 58-derived transcripts in cervical intraepithelial neoplasia. <i>Virology Journal</i> , <b>2020</b> , 17, 32	6.1	0
99	Establishment and Molecular Phenotyping of Organoids from the Squamocolumnar Junction Region of the Uterine Cervix. <i>Cancers</i> , <b>2020</b> , 12,	6.6	12
98	Genomic profiling of multiple primary cancers including synchronous lung adenocarcinoma and bilateral malignant mesotheliomas: Identification of a novel BAP1 germline variant. <i>Pathology International</i> , <b>2020</b> , 70, 775-780	1.8	3
97	Reconstructed uterine length is critical for the prevention of cervical stenosis following abdominal trachelectomy in cervical cancer patients. <i>Journal of Obstetrics and Gynaecology Research</i> , <b>2020</b> , 46, 328-336	1.9	1

96	Multistate Markov Model to Predict the Prognosis of High-Risk Human Papillomavirus-Related Cervical Lesions. <i>Cancers</i> , <b>2020</b> , 12,	6.6	5
95	Usefulness of biopsy by office hysteroscopy for endometrial cancer: A case report. <i>Molecular and Clinical Oncology</i> , <b>2020</b> , 13, 141-145	1.6	2
94	The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells. <i>Oncology Letters</i> , <b>2020</b> , 20, 153	2.6	7
93	NGS-based molecular profiling (a multi-center collaborative, observation study in Japan) highlights pathogenic variants of DNA-repair genes in advanced or recurrent endometrial cancer.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e13510-e13510	2.2	0
92	Spinal solitary fibrous tumor of the neck: Next-generation sequencing-based analysis of genomic aberrations. <i>Auris Nasus Larynx</i> , <b>2020</b> , 47, 1058-1063	2.2	2
91	Effect of murine double-minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys. <i>Cancer Science</i> , <b>2020</b> , 111, 3824-3834	6.9	4
90	Use of Cap Analysis Gene Expression to detect human papillomavirus promoter activity patterns at different disease stages. <i>Scientific Reports</i> , <b>2020</b> , 10, 17991	4.9	0
89	Desensitization strategy for hypersensitivity reactions to carboplatin in five patients with gynecological cancer. <i>Journal of Obstetrics and Gynaecology Research</i> , <b>2020</b> , 46, 2298-2304	1.9	0
88	Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>2019</b> , 155, 331-339	4.9	7
87	Mixed endometrioid and clear cell carcinoma arising from laparoscopic trocar site endometriosis. <i>Journal of Obstetrics and Gynaecology Research</i> , <b>2019</b> , 45, 1613-1618	1.9	5
86	The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation. <i>BMC Cancer</i> , <b>2019</b> , 19, 455	4.8	7
85	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. <i>Cells</i> , <b>2019</b> , 8,	7.9	4
84	Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin-fixed paraffin-embedded specimens. <i>Cancer Science</i> , <b>2019</b> , 110, 1464-1479	6.9	28
83	Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas. <i>Biochemical and Biophysical Research Communications</i> , <b>2019</b> , 513, 340-346	3.4	14
82	Activation of Nrf2/Keap1 pathway by oral Dimethylfumarate administration alleviates oxidative stress and age-associated infertility might be delayed in the mouse ovary. <i>Reproductive Biology and Endocrinology</i> , <b>2019</b> , 17, 23	5	16
81	On-chip immunofluorescence analysis of single cervical cells using an electroactive microwell array with barrier for cervical screening. <i>Biomicrofluidics</i> , <b>2019</b> , 13, 044107	3.2	4
80	Interleukin-17 is associated with expression of programmed cell death 1 ligand 1 in ovarian carcinoma. <i>Cancer Science</i> , <b>2019</b> , 110, 3068-3078	6.9	12
79	Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. <i>Nature Communications</i> , <b>2019</b> , 10, 5785	17.4	39

78	Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells. <i>Cancers</i> , <b>2019</b> , 11,	6.6	13
77	Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites. <i>International Journal of Clinical Oncology</i> , <b>2019</b> , 24, 420-427	4.2	3
76	Development of endometrioma after cervical conization. <i>Gynecological Endocrinology</i> , <b>2018</b> , 34, 341-344	2.4	
75	Activation of Nrf2 might reduce oxidative stress in human granulosa cells. <i>Molecular and Cellular Endocrinology</i> , <b>2018</b> , 470, 96-104	4.4	31
74	Intraperitoneal neutrophils activated by KRAS-induced ovarian cancer exert antitumor effects by modulating adaptive immunity. <i>International Journal of Oncology</i> , <b>2018</b> , 53, 1580-1590	4.4	5
73	Detachment from the primary site and suspension in ascites as the initial step in metabolic reprogramming and metastasis to the omentum in ovarian cancer. <i>Oncology Letters</i> , <b>2018</b> , 15, 1357-1361	2.6	11
72	Therapeutic significance of targeting survivin in cervical cancer and possibility of combination therapy with TRAIL. <i>Oncotarget</i> , <b>2018</b> , 9, 13451-13461	3.3	10
71	Kaempferol, a natural dietary flavonoid, suppresses 17 $\beta$ -estradiol-induced survivin expression and causes apoptotic cell death in endometrial cancer. <i>Oncology Letters</i> , <b>2018</b> , 16, 6195-6201	2.6	12
70	The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway. <i>BMC Cancer</i> , <b>2018</b> , 18, 1201	4.8	8
69	Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. <i>Gynecologic Oncology</i> , <b>2018</b> , 151, 381-389	4.9	63
68	The Emerging Role of FOXL2 in Regulating the Transcriptional Activation Function of Estrogen Receptor $\alpha$ An Insight Into Ovarian Folliculogenesis. <i>Reproductive Sciences</i> , <b>2017</b> , 24, 133-141	3	3
67	Low uptake of fluorodeoxyglucose in positron emission tomography/computed tomography in ovarian clear cell carcinoma may reflect glutaminolysis of its cancer stem cell-like properties. <i>Oncology Reports</i> , <b>2017</b> , 37, 1883-1888	3.5	8
66	Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance. <i>International Journal of Clinical Oncology</i> , <b>2017</b> , 22, 611-618	4.2	8
65	The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma. <i>Oncolimmunology</i> , <b>2017</b> , 6, e1338996	7.2	15
64	Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma in vitro. <i>International Journal of Oncology</i> , <b>2017</b> , 50, 1431-1438	4.4	10
63	Clear Cell Carcinoma of the Ovary <b>2017</b> , 550-556		
62	Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference. <i>Journal of Gynecologic Oncology</i> , <b>2017</b> , 28, e54	4	12
61	Intracellular signaling entropy can be a biomarker for predicting the development of cervical intraepithelial neoplasia. <i>PLoS ONE</i> , <b>2017</b> , 12, e0176353	3.7	3

60	Bevacizumab-Related Microvascular Angina and Its Management with Nicorandil. <i>International Heart Journal</i> , <b>2017</b> , 58, 803-805	1.8	11
59	Regeneration of cervical reserve cell-like cells from human induced pluripotent stem cells (iPSCs): A new approach to finding targets for cervical cancer stem cell treatment. <i>Oncotarget</i> , <b>2017</b> , 8, 40935-40943	3.3	7
58	Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations. <i>Investigational New Drugs</i> , <b>2017</b> , 35, 800-812	4.3	21
57	Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 40402-40411	3.3	36
56	Radical hysterectomy with or without para-aortic lymphadenectomy for patients with stage IB2, IIA2, and IIB cervical cancer: outcomes for a series of 308 patients. <i>International Journal of Clinical Oncology</i> , <b>2016</b> , 21, 359-366	4.2	14
55	STAT3 activity regulates sensitivity to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cervical cancer cells. <i>International Journal of Oncology</i> , <b>2016</b> , 49, 2155-2162	4.4	14
54	Cancer-associated fibroblast suppresses killing activity of natural killer cells through downregulation of poliovirus receptor (PVR/CD155), a ligand of activating NK receptor. <i>International Journal of Oncology</i> , <b>2016</b> , 49, 1297-304	4.4	27
53	A case of lymphangioliomyomatosis associated with endometrial cancer and severe systemic lupus erythematosus. <i>BMC Cancer</i> , <b>2016</b> , 16, 390	4.8	8
52	Expression of Par3 polarity protein correlates with poor prognosis in ovarian cancer. <i>BMC Cancer</i> , <b>2016</b> , 16, 897	4.8	13
51	A case of successful detection of disseminated gastrointestinal stromal tumors by ascites smear cytology using cell block preparation with DOG1 immunostaining. <i>Diagnostic Cytopathology</i> , <b>2016</b> , 44, 137-40	1.4	4
50	Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies. <i>Journal of Obstetrics and Gynaecology Research</i> , <b>2016</b> , 42, 757-62	1.9	12
49	Risk of endometrial cancer in patients with a preoperative diagnosis of atypical endometrial hyperplasia treated with total laparoscopic hysterectomy. <i>Gynecology and Minimally Invasive Therapy</i> , <b>2016</b> , 5, 69-73	1.1	5
48	Decreased expression of the plasminogen activator inhibitor type 1 is involved in degradation of extracellular matrix surrounding cervical cancer stem cells. <i>International Journal of Oncology</i> , <b>2016</b> , 48, 829-35	4.4	14
47	Systemic delivery of siRNA by actively targeted polyion complex micelles for silencing the E6 and E7 human papillomavirus oncogenes. <i>Journal of Controlled Release</i> , <b>2016</b> , 231, 29-37	11.7	37
46	Inhibition of endoplasmic reticulum (ER) stress sensors sensitizes cancer stem-like cells to ER stress-mediated apoptosis. <i>Oncotarget</i> , <b>2016</b> , 7, 51854-51864	3.3	26
45	Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging. <i>Oncotarget</i> , <b>2016</b> , 7, 29577-91	3.3	15
44	Spheroid cancer stem cells display reprogrammed metabolism and obtain energy by actively running the tricarboxylic acid (TCA) cycle. <i>Oncotarget</i> , <b>2016</b> , 7, 33297-305	3.3	41
43	MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53. <i>Oncotarget</i> , <b>2016</b> , 7, 75328-75338	3.3	22

42	Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0160330	3.7	16
41	Vaginal cancer possibly caused by pessary and immunocompromised condition: Multiple risk factors may influence vaginal cancer development. <i>Journal of Obstetrics and Gynaecology Research</i> , <b>2016</b> , 42, 748-751	1.9	2
40	Measurement of endometrial thickness by transvaginal ultrasonography to predict pathological response to medroxyprogesterone acetate in patients with grade 1 endometrioid adenocarcinoma. <i>Molecular and Clinical Oncology</i> , <b>2016</b> , 4, 492-496	1.6	8
39	Significance of survivin as a prognostic factor and a therapeutic target in endometrial cancer. <i>Gynecologic Oncology</i> , <b>2016</b> , 141, 564-569	4.9	24
38	Perspectives on targeting the phosphatidylinositol 3-kinase pathway for personalized medicine in endometrial and ovarian cancers. <i>Personalized Medicine Universe</i> , <b>2016</b> , 5, 3-7	0.3	
37	Development of ovarian cancer after excision of endometrioma. <i>Fertility and Sterility</i> , <b>2016</b> , 106, 1432-1437.e2	1.6	16
36	Clinical significance of Gremlin 1 in cervical cancer and its effects on cancer stem cell maintenance. <i>Oncology Reports</i> , <b>2016</b> , 35, 391-7	3.5	12
35	Autophagy inhibition augments resveratrol-induced apoptosis in Ishikawa endometrial cancer cells. <i>Oncology Letters</i> , <b>2016</b> , 12, 2560-2566	2.6	26
34	Enhanced efficacy against cervical carcinomas through polymeric micelles physically incorporating the proteasome inhibitor MG132. <i>Cancer Science</i> , <b>2016</b> , 107, 773-81	6.9	12
33	Characterization of novel transcripts of human papillomavirus type 16 using cap analysis gene expression technology. <i>Journal of Virology</i> , <b>2015</b> , 89, 2448-52	6.6	5
32	Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas. <i>Gynecologic Oncology</i> , <b>2015</b> , 138, 323-31	4.9	16
31	Minimization of curative surgery for treatment of early cervical cancer: a review. <i>Japanese Journal of Clinical Oncology</i> , <b>2015</b> , 45, 611-6	2.8	16
30	The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition. <i>Gynecologic Oncology</i> , <b>2015</b> , 137, 538-45	4.9	61
29	HPV-16 impairs the subcellular distribution and levels of expression of protein phosphatase 1 in cervical malignancy. <i>BMC Cancer</i> , <b>2015</b> , 15, 230	4.8	2
28	PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-VEGF pathway in endometrial cancer. <i>Gynecologic Oncology</i> , <b>2015</b> , 138, 174-80	4.9	43
27	HAND2-mediated proteolysis negatively regulates the function of estrogen receptor $\alpha$ <i>Molecular Medicine Reports</i> , <b>2015</b> , 12, 5538-44	2.9	5
26	Putative tumor suppression function of SIRT6 in endometrial cancer. <i>FEBS Letters</i> , <b>2015</b> , 589, 2274-81	3.8	23
25	Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy. <i>British Journal of Cancer</i> , <b>2015</b> , 113, 1477-83	8.7	20

24	mTOR Signaling in Endometrial Cancer: From a Molecular and Therapeutic Point of View. <i>Current Obstetrics and Gynecology Reports</i> , <b>2015</b> , 4, 1-10	0.6	10
23	CCAR2 negatively regulates nuclear receptor LXR $\beta$ by competing with SIRT1 deacetylase. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2015</b> , 149, 80-8	5.1	8
22	Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas. <i>PLoS ONE</i> , <b>2015</b> , 10, e0128066	3.7	30
21	Xanthogranulomatous inflammation of the perimetrium with infiltration into the uterine myometrium in a postmenopausal woman: a case report. <i>BMC Womens Health</i> , <b>2014</b> , 14, 82	2.9	3
20	Huge pyogenic cervical cyst with endometriosis, developing 13 years after myomectomy at the lower uterine segment: a case report. <i>BMC Womens Health</i> , <b>2014</b> , 14, 104	2.9	1
19	Non-diethylstilbestrol exposed vaginal clear cell adenocarcinoma has a common molecular profile with ovarian clear cell adenocarcinoma: A case report. <i>Gynecologic Oncology Reports</i> , <b>2014</b> , 10, 49-52	1.3	4
18	Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. <i>PLoS ONE</i> , <b>2014</b> , 9, e87220	3.7	36
17	Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients. <i>Vaccine</i> , <b>2014</b> , 32, 6233-9	4.1	66
16	Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells. <i>BMC Cancer</i> , <b>2014</b> , 14, 179	4.8	42
15	Matrix metalloproteinase (MMP)-9 in cancer-associated fibroblasts (CAFs) is suppressed by omega-3 polyunsaturated fatty acids in vitro and in vivo. <i>PLoS ONE</i> , <b>2014</b> , 9, e89605	3.7	46
14	The prevalence of cervical regulatory T cells in HPV-related cervical intraepithelial neoplasia (CIN) correlates inversely with spontaneous regression of CIN. <i>American Journal of Reproductive Immunology</i> , <b>2013</b> , 69, 134-41	3.8	20
13	Low-grade endometrial stromal sarcoma developing in a postmenopausal woman under toremifene treatment for breast cancer. <i>Journal of Obstetrics and Gynaecology Research</i> , <b>2013</b> , 39, 424-9 <sup>1.9</sup>		2
12	Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines. <i>Oncology Reports</i> , <b>2013</b> , 29, 51-7	3.5	18
11	Cyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer. <i>Oncology Reports</i> , <b>2013</b> , 30, 584-8	3.5	11
10	Combination chemotherapy with temsirolimus and trabectedin in patients with heavily pretreated clear cell carcinoma of the ovary. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e16519-e16519	2.2	
9	Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2012</b> , 22, 725-31	3.5	10
8	Effect of weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with heavily pretreated ovarian cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 5037-5037	2.2	1
7	Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. <i>PLoS ONE</i> , <b>2012</b> , 7, e37431	3.7	63

6	Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report. <i>Medical Oncology</i> , <b>2011</b> , 28, 771-4	3.7	20
5	Oral immunization with a <i>Lactobacillus casei</i> vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. <i>Vaccine</i> , <b>2010</b> , 28, 2810-7	4.1	64
4	PIK3CA cooperates with other phosphatidylinositol 3Kinase pathway mutations to effect oncogenic transformation. <i>Cancer Research</i> , <b>2008</b> , 68, 8127-36	10.1	149
3	High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. <i>Cancer Research</i> , <b>2005</b> , 65, 10669-73	10.1	395
2	Cytodiagnostic problems in uterine sarcoma. Analysis according to a novel classification of tumor growth types. <i>Acta Cytologica</i> , <b>2004</b> , 48, 181-6	3	9
1	p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. <i>Cell</i> , <b>2000</b> , 102, 849-62	56.2	1005